Join the Oncology Voice Network. Join for Free
Why and How MSLs Can Adapt the Mindset of a Lifelong Learner
lifelong learning for MSLs personal accountability in learning engaging with KOLs platforms for MSL learning social media for professional growth

Why and How MSLs Can Adapt the Mindset of a Lifelong Learner


Share This Article


Summary

In this episode, Sarah Snyder shares her insights on lifelong learning for MSLs, emphasizing the importance of personal accountability and balancing different learning types. She discusses strategies for managing decision fatigue and setting achievable learning goals, providing valuable resources and book recommendations. Sarah encourages starting before feeling fully ready and highlights the significance of performance tracking. The conversation delves into engaging with KOLs and the potential of platforms like Clubhouse and TikTok for MSLs. Sarah concludes with advice on using social media strategically for professional growth, urging listeners to take action in their learning journey.

Sarah Snyder, Associate Director, Medical Affairs at Biosplice Therapeutics discusses why it is so important for MSLs to be lifelong learners.

Sarah shares…

👉 How to apply your learning style for success

👉 Resources and platforms that may be effective for MSL learning

👉 Why personal development can be as important as scientific learnings

👉 Her personal recommendations on recent books, podcasts, etc.

👉 How to tie personal development to performance

Click for Source
lifelong learning for MSLs, personal accountability in learning, engaging with KOLs, platforms for MSL learning, social media for professional growth

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN